Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
Protocol ID
iMATRIX (GO42286)
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapse/refractory
Location
NSW, VIC, WA
Sponsor
Hoffmann-La Roche
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 17 Years
International registry ID's
NCT04774718
| Study Title | A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available |
|---|---|
| Protocol ID | iMATRIX (GO42286) |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / VIC / WA |
| Sponsor | Hoffmann-La Roche |
| Links | https://clinicaltrials.gov/ct2/show/NCT04774718 |
| Trial Status | Open |
| Trial Open Date | 26/07/2021 |
| Sites | Sydney Children's Hospital / Royal Children's Hospital / Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 17 Years |
| International registry ID's | NCT04774718 |